DCLK1 immunoreactivity in colorectal neoplasia

G. Gagliardi(Tulane University), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Charles F. Bellows(Tulane University), Monica Goswami(Tulane University)

Clinical and Experimental Gastroenterology

April 1, 2012

10.2147/ceg.s30281

Cited by 60

Related Papers

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

|Journal of Clinical Oncology|2015|2.2k

Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders

|Leukemia|2013|305

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

|Blood|2011|268

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

|Journal of Clinical Oncology|2010|268

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage

|Blood|2008|253